Financial Review: Accuray (ARAY) & Boston Scientific (BSX)

Accuray (NASDAQ: ARAY) and Boston Scientific (NYSE:BSX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.

Analyst Recommendations

This is a breakdown of current recommendations for Accuray and Boston Scientific, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Accuray 1 2 4 0 2.43
Boston Scientific 0 4 12 1 2.82

Accuray presently has a consensus price target of $7.40, suggesting a potential upside of 37.04%. Boston Scientific has a consensus price target of $30.94, suggesting a potential upside of 10.77%. Given Accuray’s higher probable upside, research analysts clearly believe Accuray is more favorable than Boston Scientific.

Volatility & Risk

Accuray has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500.

Earnings and Valuation

This table compares Accuray and Boston Scientific’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Accuray $383.41 million 1.20 -$29.57 million ($0.29) -18.62
Boston Scientific $9.05 billion 4.24 $105.00 million $0.07 399.00

Boston Scientific has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.


This table compares Accuray and Boston Scientific’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Accuray -6.09% -44.66% -5.20%
Boston Scientific 1.15% 24.27% 9.48%

Insider and Institutional Ownership

82.0% of Accuray shares are held by institutional investors. Comparatively, 91.9% of Boston Scientific shares are held by institutional investors. 3.9% of Accuray shares are held by company insiders. Comparatively, 0.7% of Boston Scientific shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.


Boston Scientific beats Accuray on 12 of the 15 factors compared between the two stocks.

About Accuray

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy. The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.

About Boston Scientific

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with's FREE daily email newsletter.

Leave a Reply